Drug Shortage Report for TEVA-BUPROPION XL
| Report ID | 230961 |
| Drug Identification Number | 02439654 |
| Brand name | TEVA-BUPROPION XL |
| Common or Proper name | BUPROPION XL 150MG SR TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | BUPROPION HYDROCHLORIDE |
| Strength(s) | 150MG |
| Dosage form(s) | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL ORAL |
| Packaging size | 500 |
| ATC code | N06AX |
| ATC description | ANTIDEPRESSANTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2024-06-20 |
| Estimated end date | 2025-02-10 |
| Actual end date | 2025-02-05 |
| Shortage status | Resolved |
| Updated date | 2025-02-06 |
| Company comments | On Allocation - Covering Key Accounts |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2024-06-21 | English | Compare |
| v2 | 2024-06-20 | French | Compare |
| v1 | 2024-06-20 | English | Compare |